SynthesisThe oncologist2026
Adherence to oral antineoplastic agents, an overview and meta-analysis.
Synthesis in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medication adherence in breast cancer: a comparative analysis of self-report tools and prescription refill data.European journal of clinical pharmacology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThe use of oral antineoplastic therapies has accelerated in recent years. Non-supervised administration of oncological therapies introduces uncertainty in regard to adherence. This review and meta-analysis reports on available literature relating to adherence, adherence-measuring methods, interventions to improve adherence, and estimates patient adherence to common oral antineoplastic therapies.
methodsA literature search was conducted in the PubMed database up to January 29, 2024 using relevant terminology for oral antineoplastic agents. Titles and abstracts of retrieved articles were screened, and full-text articles deemed of interest were reviewed. Studies suitable for meta-analysis and consistent with the analytical approach were selected based on adherence measurement methods and definitions. Random effects meta-analysis was conducted using the R package metafor and visualized with forest plots for cumulative adherence and lower-bound adherence separately.
resultsWe identified eight reviews and 75 original studies on adherence to non-endocrine oral antineoplastic agents, spanning the years from 1987 to 2023, with the vast majority published from 2010 onward. This review estimates the cumulative adherence to oral antineoplastic agents to be 84% (95% CI, 78-89) and lower-bound adherence as 71% (95% CI, 63-78).
conclusionThe definition of non-adherence and the measurement methods used across studies vary, rendering the comprehensive understanding of the subject challenging. This review identifies an adherence rate that deviates from full compliance across a wide variety of treatment regimens and tumor types, which could provide valuable insights for healthcare professionals in optimizing patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.